Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
The mechanisms involved in prion neurotoxicity are unclear,and therapies preventing accumulation of PrPSc, the disease-associatedform of prion protein (PrP), do not significantly prolong survivalin mice with central nervous system prion infection. We foundthat depleting endogenous neuronal PrPc in mice with establishedneuroinvasive prion infection reversed early spongiform changeand prevented neuronal loss and progression to clinical disease.This occurred despite the accumulation of extraneuronal PrPScto levels seen in terminally ill wild-type animals. Thus, thepropagation of nonneuronal PrPSc is not pathogenic, but arrestingthe continued conversion of PrPc to PrPSc within neurons duringscrapie infection prevents prion neurotoxicity.
Medical Research Council Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London WC1, UK.
* To whom correspondence should be addressed. E-mail: j.collinge{at}prion.ucl.ac.uk
The editors suggest the following Related Resources on Science sites:
In Science Magazine
NEWS OF THE WEEK
Jennifer Couzin (31 October 2003) Science302 (5646), 763a.
[DOI: 10.1126/science.302.5646.763a] |Summary »|Full Text »|PDF »
INTRODUCTION TO SPECIAL ISSUE
Peter Stern and Laura Helmuth (31 October 2003) Science302 (5646), 807.
[DOI: 10.1126/science.302.5646.807] |Summary »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Crystal structure of human prion protein bound to a therapeutic antibody.
S. V. Antonyuk, C. R. Trevitt, R. W. Strange, G. S. Jackson, D. Sangar, M. Batchelor, S. Cooper, C. Fraser, S. Jones, T. Georgiou, et al. (2009)
PNAS
106, 2554-2558
|Abstract »|Full Text »|PDF »
Aggregated, Wild-Type Prion Protein Causes Neurological Dysfunction and Synaptic Abnormalities.
R. Chiesa, P. Piccardo, E. Biasini, B. Ghetti, and D. A. Harris (2008)
J. Neurosci.
28, 13258-13267
|Abstract »|Full Text »|PDF »
Molecular and Transmission Characteristics of Primary-Passaged Ovine Scrapie Isolates in Conventional and Ovine PrP Transgenic Mice.
A. M. Thackray, L. Hopkins, J. Spiropoulos, and R. Bujdoso (2008)
J. Virol.
82, 11197-11207
|Abstract »|Full Text »|PDF »
Heat shock factor 1 regulates lifespan as distinct from disease onset in prion disease.
A. D. Steele, G. Hutter, W. S. Jackson, F. L. Heppner, A. W. Borkowski, O. D. King, G. J. Raymond, A. Aguzzi, and S. Lindquist (2008)
PNAS
105, 13626-13631
|Abstract »|Full Text »|PDF »
Prions Impair Bioaminergic Functions through Serotonin- or Catecholamine-derived Neurotoxins in Neuronal Cells.
S. Mouillet-Richard, N. Nishida, E. Pradines, H. Laude, B. Schneider, C. Feraudet, J. Grassi, J.-M. Launay, S. Lehmann, and O. Kellermann (2008)
J. Biol. Chem.
283, 23782-23790
|Abstract »|Full Text »|PDF »
Retrotranslocation of Prion Proteins from the Endoplasmic Reticulum by Preventing GPI Signal Transamidation.
A {gamma}-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains.
P. Spilman, P. Lessard, M. Sattavat, C. Bush, T. Tousseyn, E. J. Huang, K. Giles, T. Golde, P. Das, A. Fauq, et al. (2008)
PNAS
105, 10595-10600
|Abstract »|Full Text »|PDF »
Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.
M. D. White, M. Farmer, I. Mirabile, S. Brandner, J. Collinge, and G. R. Mallucci (2008)
PNAS
105, 10238-10243
|Abstract »|Full Text »|PDF »
Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice.
C.-H. Song, H. Furuoka, C.-L. Kim, M. Ogino, A. Suzuki, R. Hasebe, and M. Horiuchi (2008)
J. Gen. Virol.
89, 1533-1544
|Abstract »|Full Text »|PDF »
Antiprion Prophylaxis by Gene Transfer of a Soluble Prion Antagonist.
N. Genoud, D. Ott, N. Braun, M. Prinz, P. Schwarz, U. Suter, D. Trono, and A. Aguzzi (2008)
Am. J. Pathol.
172, 1287-1296
|Abstract »|Full Text »|PDF »
Physiology of the Prion Protein.
R. Linden, V. R. Martins, M. A. M. Prado, M. Cammarota, I. Izquierdo, and R. R. Brentani (2008)
Physiol Rev
88, 673-728
|Abstract »|Full Text »|PDF »
Mechanistic Insights into the Cure of Prion Disease by Novel Antiprion Compounds.
S. Webb, T. Lekishvili, C. Loeschner, S. Sellarajah, F. Prelli, T. Wisniewski, I. H. Gilbert, and D. R. Brown (2007)
J. Virol.
81, 10729-10741
|Abstract »|Full Text »|PDF »
Prion Protein Expression Differences in Microglia and Astroglia Influence Scrapie-Induced Neurodegeneration in the Retina and Brain of Transgenic Mice.
L. Kercher, C. Favara, J. F. Striebel, R. LaCasse, and B. Chesebro (2007)
J. Virol.
81, 10340-10351
|Abstract »|Full Text »|PDF »
Modulation of Proteinase K-resistant Prion Protein in Cells and Infectious Brain Homogenate by Redox Iron: Implications for Prion Replication and Disease Pathogenesis.
S. Basu, M. L. Mohan, X. Luo, B. Kundu, Q. Kong, and N. Singh (2007)
Mol. Biol. Cell
18, 3302-3312
|Abstract »|Full Text »|PDF »
Cellular prion protein (PrPC) protects neuronal cells from the effect of huntingtin aggregation.
K.-J. Lee, A. Panzera, D. Rogawski, L. E. Greene, and E. Eisenberg (2007)
J. Cell Sci.
120, 2663-2671
|Abstract »|Full Text »|PDF »
Neurotoxic and Gliotrophic Activity of a Synthetic Peptide Homologous to Gerstmann-Straussler-Scheinker Disease Amyloid Protein.
L. Fioriti, N. Angeretti, L. Colombo, A. De Luigi, A. Colombo, C. Manzoni, M. Morbin, F. Tagliavini, M. Salmona, R. Chiesa, et al. (2007)
J. Neurosci.
27, 1576-1583
|Abstract »|Full Text »|PDF »
N-Terminally Deleted Forms of the Prion Protein Activate Both Bax-Dependent and Bax-Independent Neurotoxic Pathways.
A. Li, S. J. Barmada, K. A. Roth, and D. A. Harris (2007)
J. Neurosci.
27, 852-859
|Abstract »|Full Text »|PDF »
Early and Rapid Engraftment of Bone Marrow-Derived Microglia in Scrapie..
J. Priller, M. Prinz, M. Heikenwalder, N. Zeller, P. Schwarz, F. L. Heppner, and A. Aguzzi (2006)
J. Neurosci.
26, 11753-11762
|Abstract »|Full Text »|PDF »
Neural Stem Cell Model for Prion Propagation.
O. Milhavet, D. Casanova, N. Chevallier, R. D. G. McKay, and S. Lehmann (2006)
Stem Cells
24, 2284-2291
|Abstract »|Full Text »|PDF »
Overstimulation of PrPC Signaling Pathways by Prion Peptide 106-126 Causes Oxidative Injury of Bioaminergic Neuronal Cells.
M. Pietri, A. Caprini, S. Mouillet-Richard, E. Pradines, M. Ermonval, J. Grassi, O. Kellermann, and B. Schneider (2006)
J. Biol. Chem.
281, 28470-28479
|Abstract »|Full Text »|PDF »
A systematic review of prion therapeutics in experimental models.
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.
S. Le Corre, H. W. Klafki, N. Plesnila, G. Hubinger, A. Obermeier, H. Sahagun, B. Monse, P. Seneci, J. Lewis, J. Eriksen, et al. (2006)
PNAS
103, 9673-9678
|Abstract »|Full Text »|PDF »
Amyloid Fibrils of Mammalian Prion Protein Are Highly Toxic to Cultured Cells and Primary Neurons.
V. Novitskaya, O. V. Bocharova, I. Bronstein, and I. V. Baskakov (2006)
J. Biol. Chem.
281, 13828-13836
|Abstract »|Full Text »|PDF »
Emerging pharmacotherapies for creutzfeldt-jakob disease..
Disease-related Prion Protein Forms Aggresomes in Neuronal Cells Leading to Caspase Activation and Apoptosis.
M. Kristiansen, M. J. Messenger, P.-C. Klohn, S. Brandner, J. D. F. Wadsworth, J. Collinge, and S. J. Tabrizi (2005)
J. Biol. Chem.
280, 38851-38861
|Abstract »|Full Text »|PDF »
Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
M. Nunziante, C. Kehler, E. Maas, M. U. Kassack, M. Groschup, and H. M. Schatzl (2005)
J. Cell Sci.
118, 4959-4973
|Abstract »|Full Text »|PDF »
Prion clearance in bigenic mice.
J. G. Safar, S. J. DeArmond, K. Kociuba, C. Deering, S. Didorenko, E. Bouzamondo-Bernstein, S. B. Prusiner, and P. Tremblay (2005)
J. Gen. Virol.
86, 2913-2923
|Abstract »|Full Text »|PDF »
Systematic Identification of Antiprion Drugs by High-Throughput Screening Based on Scanning for Intensely Fluorescent Targets.
U. Bertsch, K. F. Winklhofer, T. Hirschberger, J. Bieschke, P. Weber, F. U. Hartl, P. Tavan, J. Tatzelt, H. A. Kretzschmar, and A. Giese (2005)
J. Virol.
79, 7785-7791
|Abstract »|Full Text »|PDF »
Anchorless Prion Protein Results in Infectious Amyloid Disease Without Clinical Scrapie.
B. Chesebro, M. Trifilo, R. Race, K. Meade-White, C. Teng, R. LaCasse, L. Raymond, C. Favara, G. Baron, S. Priola, et al. (2005)
Science
308, 1435-1439
|Abstract »|Full Text »|PDF »
Mammalian Prion Protein Suppresses Bax-induced Cell Death in Yeast.
Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation.
C.-L. Kim, A. Karino, N. Ishiguro, M. Shinagawa, M. Sato, and M. Horiuchi (2004)
J. Gen. Virol.
85, 3473-3482
|Abstract »|Full Text »|PDF »
Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations.
C. Crozet, Y.-L. Lin, C. Mettling, C. Mourton-Gilles, P. Corbeau, S. Lehmann, and V. Perrier (2004)
J. Cell Sci.
117, 5591-5597
|Abstract »|Full Text »|PDF »
PrPSc Binding Antibodies Are Potent Inhibitors of Prion Replication in Cell Lines.
V. Beringue, D. Vilette, G. Mallinson, F. Archer, M. Kaisar, M. Tayebi, G. S. Jackson, A. R. Clarke, H. Laude, J. Collinge, et al. (2004)
J. Biol. Chem.
279, 39671-39676
|Abstract »|Full Text »|PDF »
Prions can infect primary cultured neurons and astrocytes and promote neuronal cell death.
Intrinsic Resistance of Oligodendrocytes to Prion Infection.
M. Prinz, F. Montrasio, H. Furukawa, M. E. van der Haar, P. Schwarz, T. Rulicke, O. T. Giger, K.-G. Hausler, D. Perez, M. Glatzel, et al. (2004)
J. Neurosci.
24, 5974-5981
|Abstract »|Full Text »|PDF »
Cross-Linking Cellular Prion Protein Triggers Neuronal Apoptosis in Vivo.
L. Solforosi, J. R. Criado, D. B. McGavern, S. Wirz, M. Sanchez-Alavez, S. Sugama, L. A. DeGiorgio, B. T. Volpe, E. Wiseman, G. Abalos, et al. (2004)
Science
303, 1514-1516
|Abstract »|Full Text »|PDF »